Total Credits: 0.50 including 0.50 AOA Category 1-A
CGRP Antibody Therapy: A New Frontier in Migraine Treatment
Justin DeLange, DO, FAHS
Dr. DeLange discloses he is a consultant for Amgen
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Arizona Osteopathic Medical Association (AOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
AOMA Grievance Policy: All grievances should be initially directed in writing to the AOMA Executive Director at email@example.com who will share them with the AOMA’s Program Committee. Grievances will receive a response within 30 days of receipt. If you do not receive a satisfactory response, you may notify the Council on Continuing Medical Education, AOA, 142 East Ontario St., Chicago, IL 60611.
|CGRP Antibody Therapy: A New Frontier in Migraine Treatment (712.7 KB)||31 Pages||Available after Purchase|
Justin Delange, DO is a board certified neurologist. His practice in Flagstaff, Arizona focuses on general neurology with subspecialty expertise in headache and management of facial pain. He is proficient in peripheral nerve block and Botox injections for headache treatment. His clinical interests involve treating intractable headaches such as chronic migraine; biobehavioral approaches to treatment and advocacy for headaches. Dr. DeLange completed an internal medicine internship and neurology residency at the University of Texas Health Science Center at Houston, where he also serviced as neurology chief resident. He completed a headache medicine fellowship at the Mayo Clinic Department of Neurology, Rochester, Minnesota. He is certified in the subspecialty of Headache Medicine by the United Council for Neurologic Subspecialties. Dr. DeLange is a member of the Arizona Osteopathic Medical Association, Gold Humanism Honor Society, the American Headache Society, and the American Academy of Neurology.
Dr. DeLange has no disclosures.
Please wait ...